The Efficacy of Asacol (Mesalazine) Suppository on the Treatment of Diarrhea-Induced Acute Fissure

Sponsor
Shiraz University of Medical Sciences (Other)
Overall Status
Completed
CT.gov ID
NCT05091775
Collaborator
(none)
140
1
2
7.3
19.1

Study Details

Study Description

Brief Summary

Anal fissure define as a superficial tearing in mucosa on the anoderm surface distal to dentate line . The most important factor is hard stool passing with trauma to anal mucosa. But, diarrhea diarrhea has been another important etiology that happen after some conditions like gastroenteritis, laxative over use, during chemotherapy, and ulcerative colitis exacerbation . In these conditions, it seems the change of stool PH maybe the main reason of inflammation and ulcer in acute phase.

The treatment of acute is medical management with change in bowel habits and conservative therapy such as local lubricant, local vasodilator, and warm sitz bath to improve blood supply and wound healing.

This research clinical trial is designed to show the effect of Asacol suppository in the management of acute fissure due to diarrhea. The hypothesis of this research clinical trial has been referred to the cause of acute fissure ulcer because of diarrhea.

Condition or Disease Intervention/Treatment Phase
  • Drug: Asacol is used to treat and prevent mild to moderate acute fissure disease
Phase 1/Phase 2

Detailed Description

The cases with acute anal fissure after diarrhea will included in this research clinical trial. They will be divided in two groups as an interventional group and control by blind randomization allocation. The interventional group will have received Asacol suppository 1 supp every night and Diltiazem jelly (standard management) twice per day. The control group will have received Diltiazem jelly and placebo suppository like interventional group. Both group will have used warm sitz bath with enough hydration for 10 days. Then the patients will have visited by another surgeon after 4 weeks to evaluate the healing of acute anal fissure. Pain will have performed if the patients can tolerate.

Study Design

Study Type:
Interventional
Actual Enrollment :
140 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
two groups seventy patients aged 18 to 65 years with diarrhea and subsequent acute fissure (with symptoms less than 6 weeks)two groups seventy patients aged 18 to 65 years with diarrhea and subsequent acute fissure (with symptoms less than 6 weeks)
Masking:
Single (Care Provider)
Masking Description:
Double blind
Primary Purpose:
Treatment
Official Title:
The Evaluation of the Efficacy of Asacol (Mesalazine) Suppository on the Treatment of Diarrhea-Induced Acute Fissure in Post-Chemotherapy Cancer Patients - A Randomized Controlled Trial
Actual Study Start Date :
Jun 1, 2020
Actual Primary Completion Date :
Aug 2, 2020
Actual Study Completion Date :
Jan 10, 2021

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Standard management of acute fissure(Diltiazem Jelly,supportive care,placebo suppository, sitz bath)

Patients in the first group underwent for 14 consecutive days treatment with diltiazem gel 2 times a day, a basin of warm water 2 times a day and drink daily 8-12 a glass of water will be placed with a placebo suppository.

Drug: Asacol is used to treat and prevent mild to moderate acute fissure disease
Comparison of two groups after 2 weeks in fissure wound healing, pain relief, pruritus, burning, bleeding, incontinence. Preliminary results of the study show the rate of fissure improvement 6 weeks after treatment, which is observed by clinical examination. Restoration is defined by complete epithelialization of the fissure site without scarring or residual cracks, and the secondary results will be a reduction in the amount of pain and other symptoms.
Other Names:
  • Mesalazine is used to treat and prevent mild to moderate acute fissure disease
  • Experimental: Intervention group (Asacol suppository, supportive care, placebo suppository, sitz bath)

    Patients in the second group or treatment group will be treated with diltiazem gel topically 3 times a day for 14 consecutive days, pelvis of warm water 2 times a day and drink daily 8-12 glasses of water plus Asacol anal suppository (mesalazine) are taken 1 piece every night.

    Drug: Asacol is used to treat and prevent mild to moderate acute fissure disease
    Comparison of two groups after 2 weeks in fissure wound healing, pain relief, pruritus, burning, bleeding, incontinence. Preliminary results of the study show the rate of fissure improvement 6 weeks after treatment, which is observed by clinical examination. Restoration is defined by complete epithelialization of the fissure site without scarring or residual cracks, and the secondary results will be a reduction in the amount of pain and other symptoms.
    Other Names:
  • Mesalazine is used to treat and prevent mild to moderate acute fissure disease
  • Outcome Measures

    Primary Outcome Measures

    1. Acute anal fissure after diarrhea. Standard management of acute fissure (Diltiazem Jelly, supportive care, placebo suppository, sitz bath) [2 weeks]

      bleeding anal fissure. After 2weeks the patients will visit. The score of pain, burning sensation, bleeding and improvement will be recorded in two groups. Score of pain with visual analog scale (VAS) is a tool widely used to measure pain; Scale (0-10) that higher grade means higher pain. Burning sensation (yes, no) and bleeding (yes, no) and improvement (yes, no) will be recorded

    Secondary Outcome Measures

    1. Acute anal fissure after diarrhea. Intervention group (Asacol suppository, supportive care, placebo suppository, sitz bath) [3 months]

      need surgery or botox injection. Both group including 70 patients that will visit after 2 weeks for evaluating heading acute fissure by history and physical examination. Bleeding(decrease/increase) Pruritus(decrease/increase) Wound healing (according to surgeon evaluation)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    For age between 18 and 65 years are the presence of acute anal fissure (with symptoms less than 6 weeks) following chronic diarrhea and subsequent fissure.

    Exclusion Criteria:
    • Recurrent fissure with skin appendage.

    • Long history of constipation.

    • Use of immunosuppressive drugs or corticosteroids.

    • Inflammatory bowel disease such as Crohn's disease and ulcerative colitis.

    • Pregnancy.

    • Grade 3 and 4 hemorrhoids.

    • Neurological disease.

    • Obsessive-compulsive disorder.

    • Previous history of anal surgery

    • Skin diseases such as eczema and psoriasis.

    • Sexually transmitted infections, tuberculosis.

    • Mucosal prolapse.

    • Anal fistula and pelvic radiotherapy.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Leila Ghahramani Shiraz Fars Iran, Islamic Republic of 7193635899

    Sponsors and Collaborators

    • Shiraz University of Medical Sciences

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Leila Ghahramani, Clinical Associated professor of colorectal surgery, Shiraz University of Medical Sciences
    ClinicalTrials.gov Identifier:
    NCT05091775
    Other Study ID Numbers:
    • 98-01-01-21181
    First Posted:
    Oct 25, 2021
    Last Update Posted:
    Oct 25, 2021
    Last Verified:
    Oct 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Leila Ghahramani, Clinical Associated professor of colorectal surgery, Shiraz University of Medical Sciences
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 25, 2021